NCL Method STE-3
Detection of Mycoplasma
Listed in Datasets | publication by group NCL Protocols
Version 3.0 - published on 26 May 2020 doi:10.17917/R1XZ-X580 - cite this
Licensed under these terms
Mycoplasma is a form of bacteria that lacks a nucleus and a cell wall, and are thus unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that incorporate a component derived from an animal or hybridoma cultures.
- NCL_Method_STE-3_Sep2015.pdf(PDF | 114 KB)
Cite this work
Researchers should cite this work as follows:
- Timothy Potter, Barry Neun, Ilinskaya, A., Marina Dobrovolskaia (2020). NCL Method STE-3. (Version 3.0). NCI Hub. doi:10.17917/R1XZ-X580
Relation to series
The publication is part of the series below:
Effect of blood collection tube type and time to assay on the enumeration of circulating tumor cells using the High Definition Single Cell Analysis (HD-SCA) method, laboratory of Peter Kuhn Ph.D.
The goal of this study is to characterize the effect of two pre-analytical variables on the enumeration of circulating tumor cells using the High Definition Single Cell Analysis assay. The optimized assay was then compared to the CellSearch® System.
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.